sorafenib has been researched along with pevonedistat in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (pevonedistat) | Trials (pevonedistat) | Recent Studies (post-2010) (pevonedistat) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 299 | 11 | 289 |
| Protein | Taxonomy | sorafenib (IC50) | pevonedistat (IC50) |
|---|---|---|---|
| Ubiquitin-like modifier-activating enzyme 6 | Homo sapiens (human) | 1.8 | |
| Ubiquitin-like modifier-activating enzyme 1 | Mus musculus (house mouse) | 1.5 | |
| NEDD8-activating enzyme E1 regulatory subunit | Homo sapiens (human) | 0.0471 | |
| NEDD8 | Homo sapiens (human) | 0.0047 | |
| NEDD8-activating enzyme E1 catalytic subunit | Homo sapiens (human) | 0.0033 | |
| SUMO-activating enzyme subunit 1 | Homo sapiens (human) | 8.2 | |
| SUMO-activating enzyme subunit 2 | Homo sapiens (human) | 8.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bie, P; Fang, L; Jiang, P; Li, G; Lin, X; Wu, D; Xie, CM; Yang, Z; Yin, L; Zhang, J; Zhang, L; Zhong, C | 1 |
1 other study(ies) available for sorafenib and pevonedistat
| Article | Year |
|---|---|
Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cyclopentanes; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Middle Aged; NEDD8 Protein; Neoplasm Proteins; NF-KappaB Inhibitor alpha; Pyrimidines; Sorafenib; Ubiquitin-Activating Enzymes; Ubiquitins; Xenograft Model Antitumor Assays | 2019 |